Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | HTR5A | P47898 | 2/20 | 0.35 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 2/20 | 0.32 |
| ▸ | PLAU | P00749 | 1/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.31 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.31 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.30 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.30 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.30 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6293496 | 0.78 | CA12 (0.38) | CA12CA9 | |
| Dihydrophenanthridine SCHEMBL2087461 | 0.74 | CA12 (0.56) | CA12CA9ALOX15HSD17B10GAA | |
| Dihydrophenanthridine SCHEMBL29791568 | 0.74 | CA12 (0.56) | CA12CA9ALOX15HSD17B10GAA | |
| SCHEMBL27425414 | 0.72 | CA12 (0.54) | CA12CA9ALOX15HSD17B10GAA | |
| SCHEMBL8925185 | 0.71 | ALOX15 (0.58) | CA12CA9ALOX15HSD17B10GAA | |
| SCHEMBL23194 | 0.71 | MAOA (0.46) | HSD17B10CLK4DYRK1B | |
| SCHEMBL30668800 | 0.69 | — | — | |
| SCHEMBL2041999 | 0.69 | — | — | |
| SCHEMBL1828551 | 0.69 | — | — | |
| SCHEMBL21665091 | 0.68 | CA12 (0.48) | CA12CA9ALOX15HSD17B10GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 405 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9714560-B2 | Protected scale inhibitors and methods relating thereto | HALLIBURTON ENERGY SERVICES, INC. (US) | 2017-07-25 | — | — | US | claimed |
| JP-4764833-B2 | — | — | 2011-09-07 | — | — | JP | claimed |
| EP-1735270-B1 | DIAMINO ALCOHOLS AND THEIR USE AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2010-06-30 | — | — | EP | claimed |
| US-7718675-B2 | Diamino alcohols and their use as renin inhibitor | SPEEDEL EXPERIMENTA AG (CH) | 2010-05-18 | — | — | US | claimed |
| US-20070161622-A1 | 6-Phenyl-2-hydroxy-1,3-hexanediamine derivatives, e.g., 1-{3(S)-Amino-2(S)-hydroxy-5(S)-[4-methoxy-3-(3-methoxypropoxy)benzyl]-methylheptyl}piperidin-2-one hydrochloride; treating hypertension, heart failure, glaucoma, cardiac infarction, kidney failure and restenosis | SPEEDEL EXPERIMENTA AG (CH) | 2007-07-12 | — | — | US | claimed |
| CN-1910141-A | Diamino alcohols and their use as renin inhibitors | SPEEDEL EXPERIMENTA AG (CH) | 2007-02-07 | — | — | CN | claimed |
| EP-1735270-A1 | DIAMINO ALCOHOLS AND THEIR USE AS RENIN INHIBITORS | Speedel Experimenta AG (CH) | 2006-12-27 | — | — | EP | claimed |
| WO-2005070877-A1 | DIAMINO ALCOHOLS AND THEIR USE AS RENIN INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2005-08-04 | — | — | WO | claimed |
| EP-0521827-B1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA GEIGY AG (CH) | 1996-09-25 | — | — | EP | claimed |
| CN-1068333-A | Has hydrazine analog derivative of pharmacologically active and preparation method thereof | CIBA GEIGY AG (CH) | 1993-01-27 | — | — | CN | claimed |
| EP-0521827-A1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA-GEIGY AG (CH) | 1993-01-07 | — | — | EP | claimed |
| EP-0134246-B1 | PROSTACYCLINES AND PROCESS FOR THEIR PREPARATION | TEIJIN LIMITED (JP) | 1989-08-23 | — | — | EP | claimed |
| US-11999757-B2 | Synthesis of boronate ester derivatives and uses thereof | MELINTA SUBSIDIARY CORP. (US) | 2024-06-04 | — | — | US | disclosed |
| CN-111556872-B | Synthesis of borate derivatives and uses thereof | 梅琳塔治疗公司 | 2024-05-10 | — | — | CN | disclosed |
| CN-117986153-A | Ionizable cationic lipid compound, and preparation method and application thereof | 晟迪生物医药(苏州)有限公司 | 2024-05-07 | — | — | CN | disclosed |
| EP-4356736-A2 | SYNTHESIS OF BORONATE SALTS | Melinta Therapeutics, Inc. (US) | 2024-04-24 | — | — | EP | disclosed |
| EP-0051284-B1 | NOVEL THIAPROSTAGLANDIN E1 DERIVATIVES, PROCESS FOR PRODUCTION THEREOF, AND PHARMACEUTICALS CONTAINING THESE COMPOUNDS | TEIJIN LIMITED (JP) | 1985-01-09 | — | — | EP | disclosed |
| US-4466980-A | Thiaprostaglandin E1 derivatives, process for production thereof, and pharmaceutical use thereof | TEIJIN LIMITED (JP) | 1984-08-21 | — | — | US | disclosed |
| EP-0113577-A1 | Process for preparing prostacyclins | TEIJIN LIMITED (JP) | 1984-07-18 | — | — | EP | disclosed |
| EP-0051284-A1 | Novel thiaprostaglandin E1 derivatives, process for production thereof, and pharmaceuticals containing these compounds | TEIJIN LIMITED (JP) | 1982-05-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11999757-B2 | Synthesis of boronate ester derivatives and uses thereof | ADH5, ADH1A, ADH7 | CA12 1101/4885CA9 392/4885ALOX15 699/4885 |
| US-20070161622-A1 | 6-Phenyl-2-hydroxy-1,3-hexanediamine derivatives, e.g., 1-{3(S)-Amino-2(S)-hydroxy-5(S)-[4-methoxy-3-(3-methoxypropoxy)benzyl]-methylheptyl}piperidin-2-one hydrochloride; treating hypertension, heart failure, glaucoma, cardiac infarction, kidney failure and restenosis | REN, AGTR1, AGTR2 | CA12 4877/4885CA9 4780/4885ALOX15 1797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.